Tylenol During Pregnancy Linked to Reproductive Changes in Baby Girls, Study Finds

New research examines whether prenatal Tylenol exposure may be linked to changes in ovarian and uterine development in baby girls. Here is what the study found.

A new study is drawing attention to the possible effects of taking Tylenol during pregnancy on the reproductive development of baby girls. Researchers found that prenatal exposure to Tylenol, also known as acetaminophen in the United States and paracetamol in many other countries, was associated with differences in the size of the ovaries and uterus of young female infants.

However, researchers have stressed that the findings do not prove that Tylenol causes these physical differences. The study also does not establish that girls exposed to the medicine before birth will experience fertility problems later in life.

The research adds to an ongoing discussion about medication use during pregnancy and highlights the need for further long-term studies.

What Did the Study Find?

Researchers at Rigshospitalet in Copenhagen examined 302 female infants who were three months old. Their mothers' Tylenol use was monitored during pregnancy, with researchers using periodic urine samples to assess exposure.

The infants were divided into groups based on when their mothers were first exposed to the medication. Ninety-two babies were exposed before 17 weeks of pregnancy, while 67 were first exposed after 17 weeks. Another 143 babies were born to mothers who did not use the medication during pregnancy.

The researchers reported several physical differences among infants who had been exposed to Tylenol in the womb.

On average, exposed infants had smaller ovaries, smaller uteruses and fewer ovarian follicles. Ovarian follicles are structures that contain immature eggs and play an important role in female reproductive development.

The study reported that babies exposed to Tylenol had approximately 40 percent smaller ovarian volume, 13 percent smaller uterine volume and 23 percent fewer ovarian follicles compared with infants who were not exposed.

Researchers also found that babies exposed earlier in pregnancy had lower levels of Anti-Müllerian hormone, commonly known as AMH. AMH is used as a marker associated with ovarian reserve and reproductive development.

Why Is Ovarian Development Important?

Female reproductive development begins before birth. Unlike males, females are born with the supply of eggs they will have throughout their lives.

Because of this, researchers are interested in understanding whether factors during pregnancy could influence the development of the ovaries and the number of ovarian follicles present at birth.

Previous animal research had raised questions about whether exposure to acetaminophen during pregnancy could influence reproductive development. According to the supplied report, the new study is notable because it provides similar observations in humans for the first time.

Still, the researchers have emphasized that an association between medication exposure and physical differences does not automatically mean that the medication caused those differences.

There are many factors that can influence pregnancy and fetal development, and further research is needed before scientists can determine whether the observed differences have any meaningful effect later in life.

What About Long-Term Fertility?

One of the biggest questions raised by the research is whether smaller reproductive organs or fewer ovarian follicles during infancy could eventually affect fertility.

At this stage, there is no clear answer.

Lead researcher Margit Bistrup Fischer said that determining whether these physical differences influence adult fertility or the timing of menopause will require long-term follow-up. Researchers cannot currently use the findings to predict fertility outcomes for an individual mother or child.

The study also included a separate group of 1,210 girls who were followed from infancy into adolescence. In this group, prenatal Tylenol exposure was associated with smaller uteruses at puberty and smaller ovaries during adolescence.

These findings may provide additional reasons for scientists to continue monitoring children who were exposed to the medication before birth. However, they should not be interpreted as proof that prenatal exposure will cause infertility.

Should Pregnant Women Be Worried?

Researchers involved in the study have advised women who used Tylenol during pregnancy not to panic.

This is particularly important because pain and fever can also pose health concerns during pregnancy. According to the report, current medical guidance continues to regard Tylenol as an option for treating pain and fever during pregnancy. Leaving significant pain or a high fever untreated can also carry risks for the mother and fetus.

The study therefore does not provide a reason for pregnant women to stop taking prescribed or recommended medication without first speaking with a healthcare professional.

Anyone who is pregnant and concerned about taking acetaminophen or paracetamol should discuss their individual circumstances with a doctor, midwife or other qualified healthcare professional.

How Much Tylenol Did Participants Take?

The mothers in the study generally used relatively small amounts of the medication. The report states that none of the women exceeded the maximum recommended daily dose of 4,000 milligrams.

The medication was mainly taken for common pregnancy-related problems such as headaches and musculoskeletal discomfort.

This detail is important because the research does not suggest that the findings resulted from extreme or unusually high levels of medication use.

At the same time, the study does not establish a specific amount of Tylenol that would cause reproductive changes. More research will be necessary to understand whether timing, dosage, frequency or other factors influence the observed associations.

Why More Research Is Needed

The researchers and reproductive health specialists say that longer-term studies are needed.

The key question is whether the physical differences observed during infancy and adolescence translate into measurable differences in reproductive health during adulthood.

Dr. Christian De Geyter, a reproductive medicine specialist at University Hospital of Basel in Switzerland, said the findings are consistent with existing animal research. He also argued that long-term monitoring of girls exposed to Tylenol before birth should continue through menopause.

Such research could help scientists determine whether prenatal exposure has consequences that cannot be identified during childhood or adolescence.

The Bottom Line

The new research raises important questions about the relationship between Tylenol use during pregnancy and female reproductive development. The study found associations between prenatal exposure and smaller ovaries, smaller uteruses, fewer ovarian follicles and certain hormone differences in baby girls.

However, the findings should be interpreted carefully.

The study does not prove that Tylenol caused these differences, and it does not show that women who used the medication during pregnancy will have daughters with fertility problems.

For now, pregnant women should not make changes to medication use based solely on headlines or social media discussions. Anyone concerned about pain relief during pregnancy should speak with a qualified healthcare professional who can consider their symptoms, medical history and individual circumstances.

Further research, particularly studies that follow exposed children into adulthood, will be necessary to understand the potential long-term significance of these findings.

Source

The article reports findings from research led by Margit Bistrup Fischer at Rigshospitalet in Copenhagen and published in Human Reproduction Open.

Disclaimer

This article is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for consultation with a qualified doctor, midwife, pharmacist or other healthcare professional. Do not start, stop or change any medication during pregnancy without professional medical guidance. Research findings can change as further evidence becomes available.